- 全部删除
您的购物车当前为空
Camrelizumab (SHR-1210) 是一种具有高亲和力且针对 PD-1的人源 IgG4-κ单克隆抗体。Camrelizumab 与 PD-1 的结合亲和力高达 3 nM,对 PD-1/PD-L1具有抑制作用, IC50 为 0.70 nM。Camrelizumab 具有抗肿瘤活性和耐受性,可用于研究包括 NSC-LC、ESCC、霍奇金淋巴瘤和晚期 HCC 等的癌症。


为众多的药物研发团队赋能,
让新药发现更简单!
Camrelizumab (SHR-1210) 是一种具有高亲和力且针对 PD-1的人源 IgG4-κ单克隆抗体。Camrelizumab 与 PD-1 的结合亲和力高达 3 nM,对 PD-1/PD-L1具有抑制作用, IC50 为 0.70 nM。Camrelizumab 具有抗肿瘤活性和耐受性,可用于研究包括 NSC-LC、ESCC、霍奇金淋巴瘤和晚期 HCC 等的癌症。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,330 | In stock | |
| 2 mg | ¥ 1,980 | In stock | |
| 5 mg | ¥ 3,350 | In stock | |
| 10 mg | ¥ 4,870 | In stock | |
| 25 mg | ¥ 7,660 | In stock |
Camrelizumab 相关产品
| 产品描述 | Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up to 3 nM and is inhibitory to PD-1/PD-L1 with an IC50 of 0.70 nM.Camrelizumab exhibits anti-tumor activity and is well tolerated in the study cancers including NSC-LC, ESCC, Hodgkin's lymphoma and advanced HCC. |
| 靶点活性 | PD-1/PD-L1:0.70 nM (IC50) |
| 体外活性 | 在使用结核菌素处理的外周血单个核细胞进行的T细胞增殖实验中,Camrelizumab以EC50为0.11 nM诱导T细胞增殖。在另一项测量IFN-γ分泌的类似实验中,Camrelizumab以EC50为0.38 nM诱导IFN-γ产生。[2] |
| 体内活性 | 在人源PD-1转基因小鼠模型中,Camrelizumab(3 mg/kg)与阿帕替尼(200 mg/kg 和 100 mg/kg)联合使用,肿瘤抑制率分别达到了63.1%和87.3%的。[1] |
| 别名 | 卡瑞利珠单抗, SHR-1210, Camrelizumab(anti-PD-1) |
| 分子量 | 143.7 kDa |
| CAS No. | 1798286-48-2 |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容